Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)
6.49 x 7 6.50 x 25
Post-market by (Cboe BZX)
6.51 -0.38 (-5.52%) 04/10/25 [NASDAQ]
6.49 x 7 6.50 x 25
Post-market 6.51 unch (unch) 16:01 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
6.23
Day High
6.77
Open 6.72
Previous Close 6.89 6.89
Volume 4,930,200 4,930,200
Avg Vol 3,558,210 3,558,210
Stochastic %K 12.54% 12.54%
Weighted Alpha -47.64 -47.64
5-Day Change -1.49 (-18.62%) -1.49 (-18.62%)
52-Week Range 6.20 - 12.65 6.20 - 12.65
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,116,884
  • Shares Outstanding, K 307,240
  • Annual Sales, $ 528,300 K
  • Annual Income, $ -56,110 K
  • EBIT $ 33 M
  • EBITDA $ 44 M
  • 60-Month Beta 0.79
  • Price/Sales 3.91
  • Price/Cash Flow N/A
  • Price/Book 10.35

Options Overview Details

View History
  • Implied Volatility 116.43% ( +17.99%)
  • Historical Volatility 40.97%
  • IV Percentile 99%
  • IV Rank 73.55%
  • IV High 156.04% on 04/07/25
  • IV Low 6.26% on 10/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 265
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 17,407
  • Open Int (30-Day) 16,954

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.01
  • Number of Estimates 4
  • High Estimate 0.05
  • Low Estimate -0.01
  • Prior Year -0.02
  • Growth Rate Est. (year over year) +150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.20 +5.00%
on 04/09/25
Period Open: 8.63
9.26 -29.70%
on 03/20/25
-2.12 (-24.57%)
since 03/10/25
3-Month
6.20 +5.00%
on 04/09/25
Period Open: 9.02
10.00 -34.90%
on 02/19/25
-2.51 (-27.83%)
since 01/10/25
52-Week
6.20 +5.00%
on 04/09/25
Period Open: 11.27
12.65 -48.54%
on 11/06/24
-4.76 (-42.24%)
since 04/10/24

Most Recent Stories

More News
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks

Shares of Rallybio Corporation RLYB tanked 41.2% on April 8 after the company announced its decision to stop the development of RLYB212 for the prevention of fetal and neonatal alloimmune thrombocytopenia...

FOLD : 6.51 (-5.52%)
RLYB : 0.2506 (+0.24%)
ANIP : 65.12 (-1.35%)
NCNA : 0.7290 (-2.80%)
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data

GRI Bio, Inc.’s GRI shares plummeted 36.9% on April 1 after the company announced the pricing of a public offering of stock of $5 million.Earlier in the day, the stock surged after the company reported...

FOLD : 6.51 (-5.52%)
ANIP : 65.12 (-1.35%)
GRI : 1.2100 (-6.92%)
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates

Puma Biotechnology PBYI reported fourth-quarter 2024 adjusted earnings of 43 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company reported adjusted...

FOLD : 6.51 (-5.52%)
IMCR : 25.82 (-1.15%)
PBYI : 2.74 (-5.84%)
PCRX : 23.69 (-8.32%)
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

FOLD : 6.51 (-5.52%)
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

FOLD : 6.51 (-5.52%)
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

FOLD : 6.51 (-5.52%)
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposiumâ„¢ 2025

FOLD : 6.51 (-5.52%)
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

FOLD : 6.51 (-5.52%)
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

FOLD : 6.51 (-5.52%)
Insider Sale: President and CEO of $FOLD (FOLD) Sells 7,500 Shares

Bradley L Campbell, the President and CEO of $FOLD ($FOLD), sold 7,500 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.8%...

FOLD : 6.51 (-5.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.'The company has one marketed medicine in its portfolio named Galafold which is...

See More

Key Turning Points

3rd Resistance Point 7.32
2nd Resistance Point 7.05
1st Resistance Point 6.78
Last Price 6.51
1st Support Level 6.23
2nd Support Level 5.96
3rd Support Level 5.69

See More

52-Week High 12.65
Fibonacci 61.8% 10.19
Fibonacci 50% 9.42
Fibonacci 38.2% 8.66
Last Price 6.51
52-Week Low 6.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar